CSIMarket Company Name, Ticker, Competitors, else..
 
Tricida Inc   (NASDAQ: TCDA)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 58
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Tricida Inc
Tricida Inc. is a pharmaceutical company that focuses on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company's main goal is to improve the lives of CKD patients by developing innovative treatments that target the underlying causes of the disease. Tricida's pipeline includes potential therapies for metabolic acidosis, a common complication of CKD that can lead to various health issues. Additionally, the company is committed to conducting rigorous clinical research and collaborating with healthcare professionals to advance CKD care.


   Company Address: 7000 Shoreline Court South San Francisco 94080 CA
   Company Phone Number: 429-7800   Stock Exchange / Ticker: NASDAQ TCDA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
NDRA      % 
• View Complete Report
   



Lifecore Biomedical Inc

Looking into second quarter of 2025 performance, the Major Pharmaceutical Preparations company's had sturdy revenue rise

For the September to November 24 2024 time-frame LFCR Diminishing Returns have expanded of $-0.25 per share compare to $0.39 a year ago and EPS improved from $-0.53 per share from the prior reporting period. The Revenue advanced by 7.1 % to $32.08 million from $29.96 million in the similar reporting period a year ago and sequentially revenue surged by 31.562 % from $24.39 million.

Essa Pharma Inc

Essa Pharma Inc. Reports Impressive Operating Income of $7.69 Million for Q3 2024!

The Major Pharmaceutical Preparations sector consultants start to analyze the fourth quarter of 2024 earnings. Today those consultants observe operating income of $7.694578 million, from the EPIX, as it hasn't stated any revenue thus far, for the respective July to September 30 2024 reporting period.

Veru Inc

nnRevolutionary Revenue Surge: Veru Inc. Reports Astonishing 137.446% Growth in Fiscal Year Ending September 30, 2024!nnnnn A Game-Changing Financial Milestone Signaling Robust Market Demand and Strategic Success for Veru Inc.nnn,

For the July to September 30 2024 interval Veru Inc decreased a loss per share of $-0.04 per share compare to $-0.11 a year ago and Income per Share improved from $-0.07 per share from the preceding reporting period. The revenue grew sharply by 137.446 % to $7.70 million from $3.24 million in the corresponding reporting period a year ago and sequentially Revenue doubled by 130.584 % from $3.34 million. Major Pharmaceutical Preparations company's has plainly outperformed its sector contemporaries on the revenue facet, as the Major Pharmaceutical Preparations sector report 9.73% during the matching time top-line rise so far.

Ocean Biomedical Inc

The rising business from the Major Pharmaceutical Preparations market the Ocean Biomedical Inc reported the fiscal fourth quarter of 2023, earnings

As the October to December 31 2023 reporting cycle resumes, many businesses have declared the numbers. In the thick of it, have been several businesses in the Major Pharmaceutical Preparations industry. And now, Ocean Biomedical Inc announced operating profit of $0.66 million, for the fiscal period ending December 31 2023.

Oncotelic Therapeutics Inc

Oncotelic Therapeutics Inc. Reports Steady Revenue Performance in Q3 2024, Maintaining Consistency Year-Over-Year

For the fiscal period closing September 30 2024 Oncotelic Therapeutics Inc increased a shortfall per share of $-0.01 per share compare to $0.00 a year before and from $0.00 per share from the prior reporting season. The revenue remained unchanged to $0.00 million from $0.07 million in the same reporting season a year before and sequentially from $0.00 million.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com